进入新世纪,中国青蒿素复方(Artequick)发明人、资深疟疾防治研究专家、广州中医药大学教授李国桥,根据中国和全球近50年疟疾防治的成功经验和失败教训,开始在柬埔寨和非...
基于76个网页-相关网页
Since 2001, artemisinin-based combination therapy have been recommended by WHO as the first line of falciparum malaria medication.
2001年以来,青蒿素复方作为WHO推荐治疗恶性疟的一线用药。
参考来源 - 青蒿素复方快速消灭传染源控制疟疾和根治间日疟研究·2,447,543篇论文数据，部分数据来源于NoteExpress
他们用青蒿素的一种衍生物——蒿甲醚代替青蒿素，协助改进了固定复方药。
They helped improve the fixed combination by replacing artemisinin with [one of its derivatives], artemether.
问：为何您在青蒿素耐药性并未引起关注的时候就研究青蒿素类复方药呢？
Q: Why did you research ACT for malaria at a time when there were no concerns about resistance to artemisinin?
问：世界卫生组织在早期开发青蒿素类复方药上发挥了何种作用？
Q: What role did the World Health Organization (WHO) play in the early development of ACT?
应用推荐